Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

EUR60.9 million on September 30, 2008 and EUR58.9 million on December 31, 2008. Business Highlights Clinical Highlights

Microplasmin - Back of the Eye Disease: Phase III clinical program to evaluate non-surgical treatment of patients with vitreomacular adhesion.

- Phase III program continues to progress well, with enrolment

completed for TG-MV 006 and on track for TG-MV 007

In September, ThromboGenics announced the completion of patient recruitment in the US trial (TG-MV-006) of the Phase III program with microplasmin for the non-surgical treatment of vitreomacular adhesion (a back of the eye condition). The trial recruited a total of 326 patients ahead of schedule and we anticipate reporting the results from this study by mid 2010, after a 6 month follow up period.

The second Phase III study with microplasmin, TG-MV-007, which is recruiting 320 patients in Europe and the US, is progressing well and we expect complete enrolment within the first quarter of 2010 and results of this study near the end of 2010.

This Phase III program, referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program, comprises two clinical trials, taking place in the United States (TG-MV-006 trial) and a second combined European and US study (TG-MV-007 trial). The indication for both of these Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Vitreomacular adhesion is a condition in which the vitreous has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion, which results in deterioration in the patient's vision. Both of these trials use the 125micro g dose of microplasmin.

Microplasmin - Diabetic Retinopathy: Phase II trial to evaluate microplasmin for the treatment of Diabetic Macular E
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... 2014 The ability for organizations to ... will allow individuals to perform at the highest of ... employers looking to compete in this post–recession era. ... trend, as the sector increasingly focuses on the importance ... will have real results on the organization's development and ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 7 Medicsight PLC, a subsidiary,of MGT Capital ... industry leader in the,development of Computer-Aided Detection (CAD) ... received approval from the Brazilian regulatory,agency, Agencia Nacional ... David Sumner, Chief Executive of Medicsight, commented: "This ...
... DENVER, Aug. 7 Quest Product Development, ... a $1,000,000 Small Business,Technology Transfer grant by ... the development of a next-generation endoscope. MicroFlex,technology, ... alloys and,micro-actuators that allow active control over ...
... AutoImmune Inc. (OTC,Pink Sheets: AIMM) today reported a net ... the three months ended June 30, 2008, compared with,a net ... diluted, for the,three months ended June 30, 2007. For the ... or $0.01 per share basic and diluted, compared,with net loss ...
Cached Biology Technology:Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... good examples of complex systems. Their infrastructure equipment ... for cooling, transport to supply fuel, and ICT ... the network chain is interconnected with a wider ... team of UK-based scientists has studied various aspects ... have been published in EPJ B by Gaihua ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Inter-dependent networks stress test 2
... computer-based text-searching tool developed by UT Southwestern Medical Center ... in a database for similarities, providing a more efficient ... offering scientific journal editors a new tool to thwart ... efficient at flagging publications that are highly similar, said ...
... automated sensors may soon help NOAA scientists better predict ... ice will melt, and whether soggy Pacific storms will ... of NOAAs Unmanned Aircraft Systems program. NOAA recently ... use of the crewless vehicles for wide-ranging research designed ...
... of this message: , About the Ocean Sciences ... Book Hotel Rooms by 4 February 2008 Abstracts and ... Ocean Sciences Meeting , This years meeting will offer ... and Earths water wherever it is found, from mountain ...
Cached Biology News:Computer-based tool aids research, helps thwart questionable publication practices 2Computer-based tool aids research, helps thwart questionable publication practices 3NOAA invests $3 million for unmanned aircraft system testing 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4
... Reagent B - Permeabilisation medium LEUCOPERM ... suspension with Reagent A and then permeabilising ... gives antibodies access to intracellular structures and ... cells intact. Specific formulations reduce background staining ...
... Rabbit polyclonal to JNK1 (phospho T183 + Y185) ... internal domain containing phosphorylated T183/Y185. Reactivity / ... Not yet tested in other species. Background ... including the ERK, JNK, and p38 kinases. The ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... has been designed to provide a thin film-like barrier ... a slide. This barrier creates the proper surface ... area on the slide. PAP Pen contains a ... It can be removed, if desired, by xylene ...
Biology Products: